Vivos Therapeutics Plans to File for Proposed Rights Offering

MT Newswires Live06-11

Vivos Therapeutics (VVOS) said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.

Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.

The record date would be set 30 days after the registration statement becomes effective, the company added.

Vivos Therapeutics said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.

The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price on the day before the record date.

Vivos said final terms, including the record date and distribution ratio, will be announced if the registration statement becomes effective.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642528277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642528277","market":"nz","top_or_hot":-1,"title":"Vivos Therapeutics Plans to File for Proposed Rights Offering","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> (VVOS) said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.</p><p>Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.</p><p>The record date would be set 30 days after the registration statement becomes effective, the company added.</p><p>Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.</p><p>The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price on the day before the record date.</p><p>Vivos said final terms, including the record date and distribution ratio, will be announced if the registration statement becomes effective.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics Plans to File for Proposed Rights Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics Plans to File for Proposed Rights Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> (VVOS) said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.</p><p>Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.</p><p>The record date would be set 30 days after the registration statement becomes effective, the company added.</p><p>Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.</p><p>The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price on the day before the record date.</p><p>Vivos said final terms, including the record date and distribution ratio, will be announced if the registration statement becomes effective.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VVOS","symbol_name":"Vivos Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642528277","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642528277","pubTimestamp":1781183486,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vivos Therapeutics  said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.The record date would be set 30 days after the registration statement becomes effective, the company added.Vivos Therapeutics said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VVOS":"Vivos Therapeutics","BK4196":"保健护理服务"},"translate_title":"Vivos Therapeutics计划提交拟议配股申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":1.5},"content_text":"Vivos Therapeutics (VVOS) said Thursday it plans to file a registration statement with the US Securities and Exchange Commission for a proposed rights offering that would give existing shareholders the opportunity to buy additional shares.Under the proposal, the company said shareholders would receive transferable subscription rights as a dividend if the SEC declares the registration statement effective.The record date would be set 30 days after the registration statement becomes effective, the company added.Vivos Therapeutics said each right is expected to allow holders to purchase one Vivos share at the greater of $1.25 per share or a 20% premium to the market price on the day before the record date.The rights would be tradable and remain valid for nine months, the company said, adding that shareholders who exercise their rights would also receive a second tradable right, valid for nine months, to buy additional shares at the greater of $1.75 per share or a 40% premium to the market price on the day before the record date.Vivos said final terms, including the record date and distribution ratio, will be announced if the registration statement becomes effective.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642528277","isCrawlerRequest":true}